Possibilities of combined hypolipidemic therapy in different categories of high and very high cardiovascular risk patients (a pilot study)

Aim of the study was to evaluate the efficacy and safety of the combined use of statins with ezetimibe in patients of various nosological groups of high and very high cardiovascular risk. Material and methods. A prospective interventional non-randomized study included 40 people, mean age 60.7±9.5 years, high and very high cardiovascular risk, who did not receive statin therapy or took statins without reaching the target low density lipoprotein (LDL) cholesterol values. Patients were recommended to receive high-intensity statin therapy in combination with ezetimibe for 3 months. Biochemical parameters were determined by standard enzymatic methods and the beginning of combined lipid-correcting therapy and after 3 months. Results. In patients with high cardiovascular risk, the level of total cholesterol decreased by 39.7 % 3 months after treatment (6.8 ± 2.5 and 4.7 ± 2.5 mmol/L; p = 0.0001), the level of LDL cholesterol by 52.2 % (4.6 ± 2.4 and 2.8 ± 2.2 mmol/L; p = 0.0001), the TG level by 26 % (2.7 ± 1.1 and 2.0 ± 1.0 mmol/L; p = 0.008). In the group of patients with very high cardiovascular risk, we also noted a decrease in the total cholesterol level by 39.1 % (6.4 ± 1.4 and 4.4 ± 1.2 mmol/L; p = 0.0001), the level of LDL cholesterol by 45.5 % (4.4 ± 1.4 and 2.5 ± 0.9 mmol/L; p = 0.0001). We did not find statistically significant changes in the remaining lipid parameters. LDL cholesterol targets were achieved in 64 % of patients with high and 52 % of very high cardiovascular risk. There were no significant changes in activity of alanine and aspartate amino transferases, content creatine phosphokinase, glucose and glycated hemoglobin, glomerular filtration rate. Conclusions. Initial combination therapy with statin and ezetimibe is well tolerated and can reduce LDL cholesterol levels by 2 times within 3 months in various categories of patients with high and very high cardiovascular risk.

1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемия, 2020; 1: 7–40.

2. Цыганкова О.В., Худякова А.Д., Латынцева Л.Д., Ложкина Н.Г. Сердечно-сосудистый континуум: от факторов риска до систолической сердечной недостаточности. Атеросклероз, 2017; 13 (4): 42–46. doi:10.15372/ATER20170407

3. Цыганкова О.В., Платонов Д.Ю., Бондарева З.Г. и др. Ишемическая болезнь у женщин: патогенетические и патоморфологические особенности формирования и клинического течения. Проблемы женского здоровья, 2013; 8 (4): 50–59.

4. Шальнова С.А., Деев А.Д., Метельская В.А. и др. Информированность и особенности терапии статинами у лиц с различным сердечно-сосудистым риском: исследование ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика, 2016; (4): 29–37. doi:10.15829/1728-8800-2016-4-29-37

5. Кобалава Ж.Д., Гуревич В.С., Сусеков А.В. и др. Возможности клинического применения препарата эзетимиба Отрио (АО «АКРИХИН», Россия) у пациентов высокого и очень высокого сердечно-сосудистого риска, не достигших целевых значений показателей липидного обмена. Заключение Совета экспертов. Кардиология, 2019; 59 (5S): doi:10.18087/cardio.n581

6. Zaharan N.L., Williams D., Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br. J. Clin. Pharmacol., 2013; 75: 1118–1124. doi:10.1111/j.1365-2125.2012.04403.x

7. Lim S., Oh P.C., Sakuma I., Koh K.K. How to balance cardiorenometabolic benefits and risks of statins. Atherosclerosis, 2014; 235: 644–648. doi:10.1016/j.atherosclerosis.2014.06.001

8. Mora S., Glynn R.J., Hsia J. et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation, 2010; 121: 1069Y1077. doi:10.1161/CIRCULATIONAHA.109.906479

9. Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623Y1630.

10. Ahmed S., Cannon C.P., Murohy S.A., Braunwald E. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur. Heart J., 2006; 27: 2323–2329. doi:10.1093/eurheartj/ehl220

11. Matthews D., Del Prato S., Mohan V. et al. Insights from VERIFY: Early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther., 2020; 11 (11): 2465–2476. doi:10.1007/s13300-020-00926-7

12. Ray K.K., Molemans B., Schoonen W.M. et al. EU-wide cross-sectional observational study of lipidmodifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol., 2021; 28 (11): 1279–1289. doi:10.1093/eurjpc/zwaa047. PMID:33580789

13. Toth P.P., Morrone D., Weintraub W.S. et al. Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6–24 weeks. Int. J. Clin. Pract., 2012; 66 (8) 800–813. doi:10.1111/j.1742-1241.2012.02964.x

14. Платонов Д.Ю., Костюк Т.А., Брандт А.И., Цыганкова О.В. Комплексная оценка профилактического поведения в отношении сердечно-сосудистых заболеваний и факторов риска их развития у больных гипертонической болезнью и хронической ишемической болезнью сердца. Профилактическая медицина, 2012; 15 (1): 26–31.